Complement dysregulation and disease: From genes and proteins to diagnostics and drugs

Immunobiology

Volumn 217, Issue 11, 2012, Pages 1034-1046

  de Cordoba, Santiago Rodriguez ^a   Tortajada, Agustin ^a   Harris, Claire L ^b   Morgan, B Paul ^b  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Alternative pathway; Complement; Complotype; Disease; Inflammation; Mutation; Polymorphism

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; ECULIZUMAB; MEMBRANE COFACTOR PROTEIN; TT 30; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; BACTERIAL MENINGITIS; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEFICIENCY; COMPLEMENT SYSTEM; DENSE DEPOSIT DISEASE; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; GENE MUTATION; GENE REARRANGEMENT; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GLOMERULONEPHRITIS; GLOMERULOPATHY; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPOCOMPLEMENTEMIA; INFECTION RISK; MENINGOCOCCOSIS; MULTIPLE SCLEROSIS; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATIENT SATISFACTION; PENETRANCE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84866039264     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.07.021     Document Type: Review

References (125)

1. Abarrategui-Garrido C., Martínez-Barricarte R., López-Lera A., Fariza-Requejo E., Ruivo C., Bedoya-Pérez R., Córdoba S.R.d., López-Trascasa M., Sánchez-Corral P. Proteomics-based discovery of an abnormal, internally duplicated CFHR1 protein which associates with renal pathology in a Spanish family. Mol. Immunol. 2010, 47:2200.
2. Abarrategui-Garrido C., Martinez-Barricarte R., Lopez-Trascasa M., de Cordoba S.R., Sanchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009, 114:4261.
3. Abrera-Abeleda M.A., Nishimura C., Frees K., Jones M., Maga T., Katz L.M., Zhang Y., Smith R.J. Allelic variants of complement genes associated with dense deposit disease. J. Am. Soc. Nephrol. 2011, 22:1551.
4. Alper C.A., Awdeh Z., Raum D., Yunis E.J. Complement genes of the major histocompatibility complex (complotypes), extended haplotypes and disease markers. Biochem. Soc. Symp. 1986, 51:19.
5. Asghar S.S., Pasch M.C. Therapeutic inhibition of the complement system. Y2K update. Front. Biosci. 2000, 5:E63.
6. Athanasiou Y., Voskarides K., Gale D.P., Damianou L., Patsias C., Zavros M., Maxwell P.H., Cook H.T., Demosthenous P., Hadjisavvas A., Kyriacou K., Zouvani I., Pierides A., Deltas C. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin. J. Am. Soc. Nephrol. 2011, 6:1436.
7. Atkinson J.P., Liszewski M.K., Richards A., Kavanagh D., Moulton E.A. Hemolytic uremic syndrome: an example of insufficient complement regulation on self-tissue. Ann. N. Y. Acad. Sci. 2005, 1056:144.
8. Bomback A.S., Smith R.J., Barile G.R., Zhang Y., Heher E.C., Herlitz L., Stokes M.B., Markowitz G.S., D'Agati V.D., Canetta P.A., Radhakrishnan J., Appel G.B. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin. J. Am. Soc. Nephrol. 2012, 7:748.
9. Bonifati D.M., Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol. Immunol. 2007, 44:999.
10. Brodsky R.A. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2009, 113:6522.
11. Buil A., Tregouet D.A., Souto J.C., Saut N., Germain M., Rotival M., Tiret L., Cambien F., Lathrop M., Zeller T., Alessi M.C., de Cordoba S.R., Munzel T., Wild P., Fontcuberta J., Gagnon F., Emmerich J., Almasy L., Blankenberg S., Soria J.M., Morange P.E. C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein S-independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies. Blood 2010, 115:4644.
12. Caprioli J., Bettinaglio P., Zipfel P.F., Amadei B., Daina E., Gamba S., Skerka C., Marziliano N., Remuzzi G., Noris M. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J. Am. Soc. Nephrol. 2001, 12:297.
13. Caprioli J., Castelletti F., Bucchioni S., Bettinaglio P., Bresin E., Pianetti G., Gamba S., Brioschi S., Daina E., Remuzzi G., Noris M. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum. Mol. Genet. 2003, 12:3385.
14. Cicardi M., Zanichelli A. Replacement therapy with C1 esterase inhibitors for hereditary angioedema. Drugs Today (Barc.) 2010, 46:867.
15. Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359:1221.
16. Daina E., Noris M., Remuzzi G. Eculizumab in a patient with dense-deposit disease. N. Engl. J. Med. 2012, 366:1161.
17. Davila S., Wright V.J., Khor C.C., Sim K.S., Binder A., Breunis W.B., Inwald D., Nadel S., Betts H., Carrol E.D., de Groot R., Hermans P.W., Hazelzet J., Emonts M., Lim C.C., Kuijpers T.W., Martinon-Torres F., Salas A., Zenz W., Levin M., Hibberd M.L. Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat. Genet. 2010, 42:772.
18. de Cordoba S.R., Esparza-Gordillo J., de Jorge E.G., Lopez-Trascasa M., Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol. Immunol. 2004, 41:355.
19. de Jorge E.G., Harris C.L., Esparza-Gordillo J., Carreras L., Arranz E.A., Garrido C.A., Lopez-Trascasa M., Sanchez-Corral P., Morgan B.P., de Cordoba S.R. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:240.
20. Delvaeye M., Noris M., De Vriese A., Esmon C.T., Esmon N.L., Ferrell G., Del-Favero J., Plaisance S., Claes B., Lambrechts D., Zoja C., Remuzzi G., Conway E.M. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009, 361:345.
21. Dinu V., Miller P.L., Zhao H. Evidence for association between multiple complement pathway genes and AMD. Genet. Epidemiol. 2007, 31:224.
22. Dragon-Durey M.A., Blanc C., Marliot F., Loirat C., Blouin J., Sautes-Fridman C., Fridman W.H., Fremeaux-Bacchi V. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J. Med. Genet. 2009, 46:447.
23. Dragon-Durey M.A., Fremeaux-Bacchi V., Loirat C., Blouin J., Niaudet P., Deschenes G., Coppo P., Herman Fridman W., Weiss L. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J. Am. Soc. Nephrol. 2004, 15:787.
24. Edwards A.O., Ritter R., Abel K.J., Manning A., Panhuysen C., Farrer L.A. Complement factor H polymorphism and age-related macular degeneration. Science 2005, 308:421.
25. Esparza-Gordillo J., de Jorge E.G., Buil A., Carreras Berges L., Lopez-Trascasa M., Sanchez-Corral P., de Cordoba S.R. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum. Mol. Genet. 2005, 14:703.
26. Esparza-Gordillo J., Jorge E.G., Garrido C.A., Carreras L., Lopez-Trascasa M., Sanchez-Corral P., de Cordoba S.R. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol. Immunol. 2006, 43:1769.
27. Esparza-Gordillo J., Soria J.M., Buil A., Souto J.C., Almasy L., Blangero J., de Cordoba S.R., Fontcuberta J. Genetic correlation between plasma levels of C4BP isoforms containing beta chains and susceptibility to thrombosis. J. Med. Genet. 2004, 41:e5.
28. Fagerness J.A., Maller J.B., Neale B.M., Reynolds R.C., Daly M.J., Seddon J.M. Variation near complement factor I is associated with risk of advanced AMD. Eur. J. Hum. Genet. 2009, 17:100.
29. Fakhouri F., Fremeaux-Bacchi V., Noel L.H., Cook H.T., Pickering M.C. C3 glomerulopathy: a new classification. Nat. Rev. Nephrol. 2010, 6:494.
30. Fang C.J., Richards A., Liszewski M.K., Kavanagh D., Atkinson J.P. Advances in understanding of pathogenesis of aHUS and HELLP. Br. J. Haematol. 2008, 143:336.
31. Francis N.J., McNicholas B., Awan A., Waldron M., Reddan D., Sadlier D., Kavanagh D., Strain L., Marchbank K.J., Harris C.L., Goodship T.H. A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood 2012, 119:591.
32. Fremeaux-Bacchi V., Dragon-Durey M.A., Blouin J., Vigneau C., Kuypers D., Boudailliez B., Loirat C., Rondeau E., Fridman W.H. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J. Med. Genet. 2004, 41:e84.
33. Fremeaux-Bacchi V., Miller E.C., Liszewski M.K., Strain L., Blouin J., Brown A.L., Moghal N., Kaplan B.S., Weiss R.A., Lhotta K., Kapur G., Mattoo T., Nivet H., Wong W., Gie S., Hurault de Ligny B., Fischbach M., Gupta R., Hauhart R., Meunier V., Loirat C., Dragon-Durey M.A., Fridman W.H., Janssen B.J., Goodship T.H., Atkinson J.P. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008, 112:4948.
34. Fridkis-Hareli M., Storek M., Mazsaroff I., Risitano A.M., Lundberg A.S., Horvath C.J., Holers V.M. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 2011, 118:4705.
35. Fritsche L.G., Lauer N., Hartmann A., Stippa S., Keilhauer C.N., Oppermann M., Pandey M.K., Kohl J., Zipfel P.F., Weber B.H., Skerka C. An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum. Mol. Genet. 2010, 19:4694.
36. Gale D.P., de Jorge E.G., Cook H.T., Martinez-Barricarte R., Hadjisavvas A., McLean A.G., Pusey C.D., Pierides A., Kyriacou K., Athanasiou Y., Voskarides K., Deltas C., Palmer A., Fremeaux-Bacchi V., de Cordoba S.R., Maxwell P.H., Pickering M.C. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010, 376:794.
37. Gale D.P., Pickering M.C. Regulating complement in the kidney: insights from CFHR5 nephropathy. Dis. Model Mech. 2011, 4:721.
38. Gharavi A.G., Kiryluk K., Choi M., Li Y., Hou P., Xie J., Sanna-Cherchi S., Men C.J., Julian B.A., Wyatt R.J., Novak J., He J.C., Wang H., Lv J., Zhu L., Wang W., Wang Z., Yasuno K., Gunel M., Mane S., Umlauf S., Tikhonova I., Beerman I., Savoldi S., Magistroni R., Ghiggeri G.M., Bodria M., Lugani F., Ravani P., Ponticelli C., Allegri L., Boscutti G., Frasca G., Amore A., Peruzzi L., Coppo R., Izzi C., Viola B.F., Prati E., Salvadori M., Mignani R., Gesualdo L., Bertinetto F., Mesiano P., Amoroso A., Scolari F., Chen N., Zhang H., Lifton R.P. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat. Genet. 2011, 43:321.
39. Gold B., Merriam J.E., Zernant J., Hancox L.S., Taiber A.J., Gehrs K., Cramer K., Neel J., Bergeron J., Barile G.R., Smith R.T., Hageman G.S., Dean M., Allikmets R. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat. Genet. 2006, 38:458.
40. Gorin M.B. Genetic insights into age-related macular degeneration: controversies addressing risk, causality, and therapeutics. Mol. Aspects Med. 2012.
41. Hageman G.S., Anderson D.H., Johnson L.V., Hancox L.S., Taiber A.J., Hardisty L.I., Hageman J.L., Stockman H.A., Borchardt J.D., Gehrs K.M., Smith R.J., Silvestri G., Russell S.R., Klaver C.C., Barbazetto I., Chang S., Yannuzzi L.A., Barile G.R., Merriam J.C., Smith R.T., Olsh A.K., Bergeron J., Zernant J., Merriam J.E., Gold B., Dean M., Allikmets R. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:7227.
42. Hageman G.S., Hancox L.S., Taiber A.J., Gehrs K.M., Anderson D.H., Johnson L.V., Radeke M.J., Kavanagh D., Richards A., Atkinson J., Meri S., Bergeron J., Zernant J., Merriam J., Gold B., Allikmets R., Dean M. Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Ann. Med. 2006, 38:592.
43. Hageman G.S., Mullins R.F. Molecular composition of drusen as related to substructural phenotype. Mol. Vis. 1999, 5:28.
44. Haines J.L., Hauser M.A., Schmidt S., Scott W.K., Olson L.M., Gallins P., Spencer K.L., Kwan S.Y., Noureddine M., Gilbert J.R., Schnetz-Boutaud N., Agarwal A., Postel E.A., Pericak-Vance M.A. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005, 308:419.
45. Hakobyan S., Tortajada A., Harris C.L., de Cordoba S.R., Morgan B.P. Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome. Kidney Int. 2010, 78:782.
46. Haralambous E., Dolly S.O., Hibberd M.L., Litt D.J., Udalova I.A., O'Dwyer C., Langford P.R., Simon Kroll J., Levin M. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand. J. Infect. Dis. 2006, 38:764.
47. Harris, C.L., Heurich, M., de Cordoba, S.R., Morgan, B.P., 2012. The complotype: dictating risk for inflammation and infection. Trends Immunol., Epub ahead of print; PMID 22777521.
48. Hebecker M., Jozsi M. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein. J. Biol. Chem. 2012, 287:19528.
49. Hecker L.A., Edwards A.O., Ryu E., Tosakulwong N., Baratz K.H., Brown W.L., Charbel Issa P., Scholl H.P., Pollok-Kopp B., Schmid-Kubista K.E., Bailey K.R., Oppermann M. Genetic control of the alternative pathway of complement in humans and age-related macular degeneration. Hum. Mol. Genet. 2010, 19:209.
50. Heinen S., Hartmann A., Lauer N., Wiehl U., Dahse H.M., Schirmer S., Gropp K., Enghardt T., Wallich R., Halbich S., Mihlan M., Schlotzer-Schrehardt U., Zipfel P.F., Skerka C. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009, 114:2439.
51. Hellwage J., Jokiranta T.S., Koistinen V., Vaarala O., Meri S., Zipfel P.F. Functional properties of complement factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of C3b and differential regulation by heparin. FEBS Lett. 1999, 462:345.
52. Heurich M., Martinez-Barricarte R., Francis N.J., Roberts D.L., de Cordoba S.R., Morgan B.P., Harris C.L. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:8761.
53. Hogasen K., Jansen J.H., Mollnes T.E., Hovdenes J., Harboe M. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J. Clin. Invest. 1995, 95:1054.
54. Hughes A.E., Orr N., Esfandiary H., Diaz-Torres M., Goodship T., Chakravarthy U. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat. Genet. 2006, 38:1173.
55. Ingram G., Hakobyan S., Hirst C., Harris C., Loveless S., Mitchell J., Pickersgill T., Robertson N., Morgan B. Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Mult. Scler. 2012.
56. Ingram G., Hakobyan S., Hirst C.L., Harris C.L., Pickersgill T.P., Cossburn M.D., Loveless S., Robertson N.P., Morgan B.P. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 2010, 133:1602.
57. Ingram G., Hakobyan S., Robertson N.P., Morgan B.P. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin. Exp. Immunol. 2009, 155:128.
58. Ingram G., Hakobyan S., Robertson N.P., Morgan B.P. Elevated plasma C4a levels in multiple sclerosis correlate with disease activity. J. Neuroimmunol. 2010, 223:124.
59. Jozsi M., Licht C., Strobel S., Zipfel S.L., Richter H., Heinen S., Zipfel P.F., Skerka C. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008, 111:1512.
60. Jozsi M., Zipfel P.F. Factor H family proteins and human diseases. Trends Immunol. 2008, 29:380.
61. Kavanagh D., Kemp E.J., Mayland E., Winney R.J., Duffield J.S., Warwick G., Richards A., Ward R., Goodship J.A., Goodship T.H. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2005, 16:2150.
62. Kemper C., Atkinson J.P., Hourcade D.E. Properdin: emerging roles of a pattern-recognition molecule. Annu. Rev. Immunol. 2010, 28:131.
63. Klein R.J., Zeiss C., Chew E.Y., Tsai J.Y., Sackler R.S., Haynes C., Henning A.K., SanGiovanni J.P., Mane S.M., Mayne S.T., Bracken M.B., Ferris F.L., Ott J., Barnstable C., Hoh J. Complement factor H polymorphism in age-related macular degeneration. Science 2005, 308:385.
64. Lachmann P.J. The amplification loop of the complement pathways. Adv. Immunol. 2009, 104:115.
65. Landau D., Shalev H., Levy-Finer G., Polonsky A., Segev Y., Katchko L. Familial hemolytic uremic syndrome associated with complement factor H deficiency. J. Pediatr. 2001, 138:412.
66. Lassmann H. Recent neuropathological findings in MS - implications for diagnosis and therapy. J. Neurol. 2004, 251(Suppl. 4):IV2.
67. Levy M., Halbwachs-Mecarelli L., Gubler M.C., Kohout G., Bensenouci A., Niaudet P., Hauptmann G., Lesavre P. H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int. 1986, 30:949.
68. Licht C., Heinen S., Jozsi M., Loschmann I., Saunders R.E., Perkins S.J., Waldherr R., Skerka C., Kirschfink M., Hoppe B., Zipfel P.F. Deletion of Lys224 in regulatory domain 4 of factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int. 2006, 70:42.
69. Linington C., Morgan B.P., Scolding N.J., Wilkins P., Piddlesden S., Compston D.A. The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain 1989, 112(Pt 4):895.
70. Liszewski M.K., Leung M.K., Schraml B., Goodship T.H., Atkinson J.P. Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. Mol. Immunol. 2007, 44:1559.
71. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000, 47:707.
72. Mache C.J., Acham-Roschitz B., Fremeaux-Bacchi V., Kirschfink M., Zipfel P.F., Roedl S., Vester U., Ring E. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 2009, 4:1312.
73. Malik T.H., Lavin P.J., de Jorge E.G., Vernon K.A., Rose K.L., Patel M.P., de Leeuw M., Neary J.J., Conlon P.J., Winn M.P., Pickering M.C. A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J. Am. Soc. Nephrol. 2012.
74. Maller J., George S., Purcell S., Fagerness J., Altshuler D., Daly M.J., Seddon J.M. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat. Genet. 2006, 38:1055.
75. Manuelian T., Hellwage J., Meri S., Caprioli J., Noris M., Heinen S., Jozsi M., Neumann H.P., Remuzzi G., Zipfel P.F. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J. Clin. Invest. 2003, 111:1181.
76. Martinez-Barricarte R., Heurich M., Valdes-Canedo F., Vazquez-Martul E., Torreira E., Montes T., Tortajada A., Pinto S., Lopez-Trascasa M., Morgan B.P., Llorca O., Harris C.L., de Cordoba S.R. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J. Clin. Invest. 2010, 120:3702.
77. Martinez-Barricarte R., Pianetti G., Gautard R., Misselwitz J., Strain L., Fremeaux-Bacchi V., Skerka C., Zipfel P.F., Goodship T., Noris M., Remuzzi G., de Cordoba S.R. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2008, 19:639.
78. Martinez-Barricarte R., Recalde S., Fernandez-Robredo P., Millan I., Olavarrieta L., Vinuela A., Perez-Perez J., Garcia-Layana A., de Cordoba S.R. Relevance of complement factor H-related 1 (CFHR1) genotypes in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2012, 53:1087.
79. McRae J.L., Duthy T.G., Griggs K.M., Ormsby R.J., Cowan P.J., Cromer B.A., McKinstry W.J., Parker M.W., Murphy B.F., Gordon D.L. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein. J. Immunol. 2005, 174:6250.
80. Monteferrante G., Brioschi S., Caprioli J., Pianetti G., Bettinaglio P., Bresin E., Remuzzi G., Noris M. Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. Mol. Immunol. 2007, 44:1704.
81. Montes T., Tortajada A., Morgan B.P., de Cordoba S.R., Harris C.L. Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4366.
82. Moore I., Strain L., Pappworth I., Kavanagh D., Barlow P.N., Herbert A.P., Schmidt C.Q., Staniforth S.J., Holmes L.V., Ward R., Morgan L., Goodship T.H., Marchbank K.J. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010, 115:379.
83. Morariu M.A., Dalmasso A.P. Experimental allergic encephalomyelitis in cobra venom factor-treated and C4-deficient guinea pigs. Ann. Neurol. 1978, 4:427.
84. Muller-Eberhard H.J. The killer molecule of complement. J. Invest. Dermatol. 1985, 85:47s.
85. Narendra U., Pauer G.J., Hagstrom S.A. Genetic analysis of complement factor H related 5, CFHR5, in patients with age-related macular degeneration. Mol. Vis. 2009, 15:731.
86. Neumann H.P., Salzmann M., Bohnert-Iwan B., Mannuelian T., Skerka C., Lenk D., Bender B.U., Cybulla M., Riegler P., Konigsrainer A., Neyer U., Bock A., Widmer U., Male D.A., Franke G., Zipfel P.F. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J. Med. Genet. 2003, 40:676.
87. Noris M., Brioschi S., Caprioli J., Todeschini M., Bresin E., Porrati F., Gamba S., Remuzzi G. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003, 362:1542.
88. Noris M., Remuzzi G. Hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2005, 16:1035.
89. Nurnberger J., Philipp T., Witzke O., Opazo Saez A., Vester U., Baba H.A., Kribben A., Zimmerhackl L.B., Janecke A.R., Nagel M., Kirschfink M. Eculizumab for atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009, 360:542.
90. Ohali M., Shalev H., Schlesinger M., Katz Y., Kachko L., Carmi R., Sofer S., Landau D. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H. Pediatr. Nephrol. 1998, 12:619.
91. Pangburn M.K., Schreiber R.D., Muller-Eberhard H.J. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J. Exp. Med. 1981, 154:856.
92. Perez-Caballero D., Gonzalez-Rubio C., Gallardo M.E., Vera M., Lopez-Trascasa M., de Cordoba S.R., Sanchez-Corral P. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 2001, 68:478.
93. Pickering M.C., Cook H.T., Warren J., Bygrave A.E., Moss J., Walport M.J., Botto M. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat. Genet. 2002, 31:424.
94. Pickering M.C., de Jorge E.G., Martinez-Barricarte R., Recalde S., Garcia-Layana A., Rose K.L., Moss J., Walport M.J., Cook H.T., de Cordoba S.R., Botto M. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J. Exp. Med. 2007, 204:1249.
95. Raychaudhuri S., Iartchouk O., Chin K., Tan P.L., Tai A.K., Ripke S., Gowrisankar S., Vemuri S., Montgomery K., Yu Y., Reynolds R., Zack D.J., Campochiaro B., Campochiaro P., Katsanis N., Daly M.J., Seddon J.M. A rare penetrant mutation in CFH confers high risk of age-related macular degeneration. Nat. Genet. 2011, 43:1232.
96. Reynolds R., Hartnett M.E., Atkinson J.P., Giclas P.C., Rosner B., Seddon J.M. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest. Ophthalmol. Vis. Sci. 2009, 50:5818.
97. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785.
98. Richards A., Buddles M.R., Donne R.L., Kaplan B.S., Kirk E., Venning M.C., Tielemans C.L., Goodship J.A., Goodship T.H. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am. J. Hum. Genet. 2001, 68:485.
99. Richards A., Kemp E.J., Liszewski M.K., Goodship J.A., Lampe A.K., Decorte R., Muslumanoglu M.H., Kavukcu S., Filler G., Pirson Y., Wen L.S., Atkinson J.P., Goodship T.H. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12966.
100. Risitano A.M., Notaro R., Marando L., Serio B., Ranaldi D., Seneca E., Ricci P., Alfinito F., Camera A., Gianfaldoni G., Amendola A., Boschetti C., Di Bona E., Fratellanza G., Barbano F., Rodeghiero F., Zanella A., Iori A.P., Selleri C., Luzzatto L., Rotoli B. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009, 113:4094.
101. Rose K.L., Paixao-Cavalcante D., Fish J., Manderson A.P., Malik T.H., Bygrave A.E., Lin T., Sacks S.H., Walport M.J., Cook H.T., Botto M., Pickering M.C. Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J. Clin. Invest. 2008, 118:608.
102. Rother R.P., Rollins S.A., Mojcik C.F., Brodsky R.A., Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 2007, 25:1256.
103. Roumenina L.T., Frimat M., Miller E.C., Provot F., Dragon-Durey M.A., Bordereau P., Bigot S., Hue C., Satchell S.C., Mathieson P.W., Mousson C., Noel C., Sautes-Fridman C., Halbwachs-Mecarelli L., Atkinson J.P., Lionet A., Fremeaux-Bacchi V. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 2012, 119:4182.
104. Sanchez-Corral P., Criado Garcia O., de Cordoba S.R. Isoforms of human C4b-binding protein. I. Molecular basis for the C4BP isoform pattern and its variations in human plasma. J. Immunol. 1995, 155:4030.
105. Sanchez-Corral P., Gonzalez-Rubio C., de Cordoba S.R., Lopez-Trascasa M. Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol. Immunol. 2004, 41:81.
106. Sanchez-Corral P., Perez-Caballero D., Huarte O., Simckes A.M., Goicoechea E., Lopez-Trascasa M., de Cordoba S.R. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 2002, 71:1285.
107. Scholl H.P., Charbel Issa P., Walier M., Janzer S., Pollok-Kopp B., Borncke F., Fritsche L.G., Chong N.V., Fimmers R., Wienker T., Holz F.G., Weber B.H., Oppermann M. Systemic complement activation in age-related macular degeneration. PLoS One 2008, 3:e2593.
108. Servais A., Noel L.H., Roumenina L.T., Le Quintrec M., Ngo S., Dragon-Durey M.A., Macher M.A., Zuber J., Karras A., Provot F., Moulin B., Grunfeld J.P., Niaudet P., Lesavre P., Fremeaux-Bacchi V. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012, March. (Epub ahead of print).
109. Skerka C., Zipfel P.F. Complement factor H related proteins in immune diseases. Vaccine 2008, 26(Suppl. 8):I9.
110. Smailhodzic D., Klaver C.C., Klevering B.J., Boon C.J., Groenewoud J.M., Kirchhof B., Daha M.R., den Hollander A.I., Hoyng C.B. Risk alleles in CFH and ARMS2 are independently associated with systemic complement activation in age-related macular degeneration. Ophthalmology 2012, 119:339.
111. Smith R.J., Alexander J., Barlow P.N., Botto M., Cassavant T.L., Cook H.T., de Cordoba S.R., Hageman G.S., Jokiranta T.S., Kimberling W.J., Lambris J.D., Lanning L.D., Levidiotis V., Licht C., Lutz H.U., Meri S., Pickering M.C., Quigg R.J., Rops A.L., Salant D.J., Sethi S., Thurman J.M., Tully H.F., Tully S.P., van der Vlag J., Walker P.D., Wurzner R., Zipfel P.F. New approaches to the treatment of dense deposit disease. J. Am. Soc. Nephrol. 2007, 18:2447.
112. Smith R.J., Harris C.L., Pickering M.C. Dense deposit disease. Mol. Immunol. 2011, 48:1604.
113. Takeda J., Miyata T., Kawagoe K., Iida Y., Endo Y., Fujita T., Takahashi M., Kitani T., Kinoshita T. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993, 73:703.
114. Tortajada A., Montes T., Martinez-Barricarte R., Morgan B.P., Harris C.L., de Cordoba S.R. The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum. Mol. Genet. 2009, 18:3452.
115. Tortajada A., Pinto S., Martinez-Ara J., Lopez-Trascasa M., Sanchez-Corral P., de Cordoba S.R. Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance. Kidney Int. 2012, 81:56.
116. Veerhuis R., Nielsen H.M., Tenner A.J. Complement in the brain. Mol. Immunol. 2011, 48:1592.
117. Venables J.P., Strain L., Routledge D., Bourn D., Powell H.M., Warwicker P., Diaz-Torres M.L., Sampson A., Mead P., Webb M., Pirson Y., Jackson M.S., Hughes A., Wood K.M., Goodship J.A., Goodship T.H. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med. 2006, 3:e431.
118. Vivarelli M., Pasini A., Emma F. Eculizumab for the treatment of dense-deposit disease. N. Engl. J. Med. 2012, 366:1163.
119. Warwicker P., Goodship T.H., Donne R.L., Pirson Y., Nicholls A., Ward R.M., Turnpenny P., Goodship J.A. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 1998, 53:836.
120. Weismann D., Hartvigsen K., Lauer N., Bennett K.L., Scholl H.P., Charbel Issa P., Cano M., Brandstatter H., Tsimikas S., Skerka C., Superti-Furga G., Handa J.T., Zipfel P.F., Witztum J.L., Binder C.J. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 2011, 478:76.
121. Woehrl B., Brouwer M.C., Murr C., Heckenberg S.G., Baas F., Pfister H.W., Zwinderman A.H., Morgan B.P., Barnum S.R., van der Ende A., Koedel U., van de Beek D. Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. J. Clin. Invest. 2011, 121:3943.
122. Yates J.R., Sepp T., Matharu B.K., Khan J.C., Thurlby D.A., Shahid H., Clayton D.G., Hayward C., Morgan J., Wright A.F., Armbrecht A.M., Dhillon B., Deary I.J., Redmond E., Bird A.C., Moore A.T. Complement C3 variant and the risk of age-related macular degeneration. N. Engl. J. Med. 2007, 357:553.
123. Zhao J., Wu H., Khosravi M., Cui H., Qian X., Kelly J.A., Kaufman K.M., Langefeld C.D., Williams A.H., Comeau M.E., Ziegler J.T., Marion M.C., Adler A., Glenn S.B., Alarcon-Riquelme M.E., Pons-Estel B.A., Harley J.B., Bae S.C., Bang S.Y., Cho S.K., Jacob C.O., Vyse T.J., Niewold T.B., Gaffney P.M., Moser K.L., Kimberly R.P., Edberg J.C., Brown E.E., Alarcon G.S., Petri M.A., Ramsey-Goldman R., Vila L.M., Reveille J.D., James J.A., Gilkeson G.S., Kamen D.L., Freedman B.I., Anaya J.M., Merrill J.T., Criswell L.A., Scofield R.H., Stevens A.M., Guthridge J.M., Chang D.M., Song Y.W., Park J.A., Lee E.Y., Boackle S.A., Grossman J.M., Hahn B.H., Goodship T.H., Cantor R.M., Yu C.Y., Shen N., Tsao B.P. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet. 2011, 7:e1002079.
124. Zipfel P.F., Edey M., Heinen S., Jozsi M., Richter H., Misselwitz J., Hoppe B., Routledge D., Strain L., Hughes A.E., Goodship J.A., Licht C., Goodship T.H., Skerka C. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 2007, 3:e41.
125. Zipfel P.F., Jokiranta T.S., Hellwage J., Koistinen V., Meri S. The factor H protein family. Immunopharmacology 1999, 42:53.